Large Study Finds Treatment Combination Leads to Long-Term Mesothelioma Survival

long-term mesothelioma survival

There is more evidence that surgery and intraperitoneal chemotherapy can lead to long-term mesothelioma survival. The news comes from an Australian study of more than 1,200 cancer patients. The study finds that one in five peritoneal mesothelioma patients who had this treatment combination were still alive 10 years later.  Peritoneal Cancer Survival with Surgery  Peritoneal cancers occur on the lining of the abdomen. Peritoneal mesothelioma starts on this peritoneal membrane. Some other peritoneal cancers start elsewhere in the body and spread to the peritoneum. The new Australian study analyzed the cases of peritoneal cancer patients who had cytoreductive surgery between 1996 and 2018. Cytoreductive surgery aims to remove as much of the cancer as possible. Past studies have found that … Continue reading Large Study Finds Treatment Combination Leads to Long-Term Mesothelioma Survival »

Spotting the BAP1 Gene Mutation in Mesothelioma Patients

BAP1 gene mutation

New guidelines may make it easier to tell which mesothelioma patients contracted the disease because of a BAP1 gene mutation. The knowledge could have an impact on mesothelioma treatment planning. BAP1 stands for BRCA associated protein-1. People who have an inherited BAP1 gene mutation face a higher risk for several conditions, including malignant mesothelioma.  Very few mesothelioma patients have the mutation and gene testing is not routine. So researchers at a top US cancer center have developed a set of screening criteria. The criteria may help predict which mesothelioma patients could benefit from genetic testing. Testing for the Altered Gene Mesothelioma is just one of the conditions associated with the inherited BAP1 gene mutation. People with this condition are also … Continue reading Spotting the BAP1 Gene Mutation in Mesothelioma Patients »

Shorter Mesothelioma Survival Again Linked to Higher PD-L1 Levels

shorter mesothelioma linked to protein

Patients with the rarest mesothelioma subtypes tend to experience shorter mesothelioma survival. Now, new mesothelioma research suggests that may have something to do with a protein called PD-L1. French researchers studied the PD-L1 levels in the tumors of 214 mesothelioma patients. They compared the levels with each patient’s subtype and their treatment outcome.  The results may help explain cases of shorter mesothelioma survival, especially among patients with sarcomatoid or biphasic mesothelioma subtypes.  PD-L1 Levels and Shorter Mesothelioma Survival Programmed death ligand 1 (PD-L1) is one of the proteins that helps mesothelioma cells and other cancers “hide” from the immune system.  Normally, the immune system finds and destroys renegade cells. But if a patient’s mesothelioma tumor expresses higher amount of PD-L1, … Continue reading Shorter Mesothelioma Survival Again Linked to Higher PD-L1 Levels »

Mesothelioma Survival Rates Have Remained Flat for Decades

mesothelioma survival rates

Mesothelioma survival rates have stayed steady for decades, even though treatments are improving. According to more than 25 years worth of data from the National Mesothelioma Virtual Bank, people with malignant mesothelioma live a median of 15 months. That number has changed little since 1990. Charting Mesothelioma Patients Over Time Researchers from several major US cancer centers compiled the new report. The goal was to chart mesothelioma survival rates over time and identify factors that impact them. The group evaluated mesothelioma survival rates from 888 cases of pleural and peritoneal mesothelioma in the NMVB. The NMVB houses information on more than 1400 mesothelioma cases diagnosed between 1990 and 2017. Overall mesothelioma survival rates stayed right around 15 months. But there … Continue reading Mesothelioma Survival Rates Have Remained Flat for Decades »

Adjuvant Radiotherapy Most Effective for Pleural Mesothelioma in Early Stages

adjuvant radiotherapy for esothelioma

New research shows adjuvant radiotherapy is most likely to help pleural mesothelioma patients in the early stages of the disease. By the time mesothelioma is at Stage III or Stage IV, adjuvant radiotherapy is unlikely to improve survival. Researchers at MD Anderson Cancer Center in Texas conducted the study on more than 2,500 pleural mesothelioma patients. Their results appear in the most recent issue of the Journal of Thoracic Disease. The study could help mesothelioma patients and doctors make more informed choices about their care. Defining the Stages of Pleural Mesothelioma The four stages of mesothelioma relate to the severity of the cancer and how far it has spread. In Stage I mesothelioma, the tumor is confined to the pleural … Continue reading Adjuvant Radiotherapy Most Effective for Pleural Mesothelioma in Early Stages »

Minimally Invasive Mesothelioma Diagnosis from Lung Fluid

minimally invasive mesothelioma diagnosis

Minimally invasive mesothelioma diagnosis with lung fluid may be just as effective as a tissue biopsy. That’s according to Australian mesothelioma researchers. Australia was once one of the biggest producers of asbestos and now has some of the highest mesothelioma rates in the world. It is also home to high-level mesothelioma research. In the latest study, scientists ran a meta-analysis comparing surgical biopsy with a minimally invasive mesothelioma diagnosis tool called cytology. Their conclusion is that surgery may not always be necessary to diagnose malignant mesothelioma. Tissue Versus Lung Fluid Malignant mesothelioma is a fatal cancer caused by exposure to asbestos. It is challenging to diagnose because the symptoms are often vague and similar to other less serious conditions. Doctors … Continue reading Minimally Invasive Mesothelioma Diagnosis from Lung Fluid »

Systemic Inflammation Linked to Shorter Mesothelioma Survival

systemic inflammation

Mesothelioma patients whose bodies respond to the illness with systemic inflammation are less likely to survive. Chinese researchers have linked a measure of systemic inflammation called SII to shorter survival in people with pleural mesothelioma. The new study involved 97 people with confirmed malignant mesothelioma. It suggests that SII could be a simple, non-invasive way to determine mesothelioma prognosis. What is SII? SII stands for “systemic immune-inflammation index”. When a body is under stress, such as when it is fighting mesothelioma, the innate immune system kicks into action. Certain kinds of white blood cells and proteins are released. The result is systemic inflammation. SII can be determined with a blood test. The test measures the levels of white blood cells … Continue reading Systemic Inflammation Linked to Shorter Mesothelioma Survival »

When Pleural and Peritoneal Mesothelioma Occur Together

pleural and peritoneal mesothelioma

Pleural and peritoneal mesothelioma rarely occur at the same time. But when they do, there is still hope for treatment. That message comes from a new study conducted at Columbia University and published in the Annals of Surgical Oncology. The researchers analyzed cases of patients diagnosed with both pleural and peritoneal mesothelioma at Columbia. They were looking for the factors that impacted their survival and the most effective ways to treat them. Comparing Pleural and Peritoneal Mesothelioma There are two primary types of malignant mesothelioma, the type of cancer most closely associated with asbestos exposure. The most common type is pleural mesothelioma. With this type, the first tumors show up on the membrane that surrounds the lungs (pleura). Chest pain, … Continue reading When Pleural and Peritoneal Mesothelioma Occur Together »

Mesothelioma Tumor Progression Can be Tracked With Blood Test

mesothelioma tumor progression

Italian researchers say it’s possible to monitor mesothelioma tumor progression with a simple blood test. They make their case in a Letter to the Editor in the latest edition of the Journal of Thoracic Oncology. The researchers say blood serum levels of the protein mesothelin correlate closely with tumor volume in malignant pleural mesothelioma patients. They are recommending that the blood test be used alongside CT to track mesothelioma tumor progression. The Importance of Monitoring Mesothelioma Tumor Progression Pleural mesothelioma is a rare cancer with a grim prognosis. Mesothelioma tumors tend to grow and spread quickly. Doctors have to carefully monitor mesothelioma tumor progression to tell if a treatment is working. Most mesothelioma patients have chemotherapy with Alimta (pemetrexed) and … Continue reading Mesothelioma Tumor Progression Can be Tracked With Blood Test »

Lower-Volume Centers Less Likely to Follow Mesothelioma Treatment Guidelines

mesothelioma treatment guidelines

Mesothelioma patients need to beware of low-volume centers that are less likely to follow mesothelioma treatment guidelines. That is the message from a new study based on data from the National Cancer Institute. The study was run by doctors at Cedars-Sinai Medical Center in Los Angeles. It shows that treatment centers that do not see a lot of mesothelioma cases are less likely to follow the life-saving mesothelioma treatment guidelines. As a result, patients treated in these lower-volume facilities tend to have shorter mesothelioma survival. What are the Mesothelioma Treatment Guidelines? Malignant pleural mesothelioma is a cancer that occurs on the membrane that surrounds the lungs. It is extremely rare and difficult to treat. Many hospitals and doctors never see … Continue reading Lower-Volume Centers Less Likely to Follow Mesothelioma Treatment Guidelines »

Get your free copy of
“Surviving Mesothelioma” Today!